EGFR and neoplasm: Over the number of evaluable samples from any tumor, the mutated genes with the highest prevalence (95% CI) were as follows: TP53, 51.5% (46.5%, 56.5%); KRAS, 29.2% (24.8%, 33.9%); APC, 17.3% (13.8%, 21.4%); EGFR, 10.4% (7.6%, 13.8%); and BRAF, 8.70% (6.10%, 11.8%).